Asssigment

2

2

Pathophysiology of Colon Cancer

Student Name

MSN5150

Advanced Pathophysiology

Miami Regional University

Professor: Dr. Caridad Hernandez

March 26th, 2024

Introduction

Colon cancer, also known as colorectal cancer, is a prevalent and potentially life-threatening disease characterized by the abnormal growth of cells in the colon, which is the first and longest segment of the large intestine. As a crucial component of the digestive system, the colon plays a vital role in the absorption of nutrients and the elimination of waste from the body. Therefore, any disruption to its normal function can have significant implications for overall health and well-being (mayoclinic, 2022). Understanding the pathophysiology of colon cancer is essential for effectively combating this disease. By delving into the underlying mechanisms that drive its development and progression, researchers and healthcare professionals can gain valuable insights into potential diagnostic and therapeutic strategies. Moreover, a deeper comprehension of the molecular and cellular processes involved this problem can inform the development of targeted therapies aimed at improving patient outcomes and reducing mortality rates. In this investigation, we will provide a comprehensive overview of colon cancer pathophysiology, exploring its molecular basis, genetic factors, environmental influences, and immunological pathways.

Literature Review

The literature review serves as a comprehensive exploration into the molecular pathophysiology of colorectal cancer (CRC), aiming to synthesize current research findings and elucidate the complex mechanisms underlying disease initiation, progression, and treatment response. By conducting a thorough analysis of peer-reviewed articles, research studies, and scholarly sources, researchers endeavor to consolidate existing knowledge and identify gaps in understanding, thereby informing future research directions and clinical practice.

Chakrabarti et al. (2020) contribute to this endeavor by examining the current standard of care for CRC, emphasizing the challenges posed by disease recurrence and the limitations of existing treatment paradigms. Despite advancements in screening methods and therapeutic options such as surgery and adjuvant chemotherapy, CRC remains a leading cause of mortality worldwide. Their research underscores the urgent need for innovative approaches to enhance patient outcomes, including the development of novel biomarkers for patient stratification and tailored therapeutic interventions.

Malki et al. (2020) further enrich the literature by exploring the multifactorial nature of CRC etiology, highlighting the contributions of genetic, familial, and environmental factors to disease susceptibility and progression. Their investigation emphasizes the importance of elucidating the molecular pathways involved in CRC development to facilitate early detection, risk assessment, and personalized treatment strategies. By shedding light on the intricate interplay between genetic mutations, environmental exposures, and tumorigenic processes, Malki et al. underscore the complexity of CRC pathogenesis and the necessity of a multidisciplinary approach to disease management.

Sarandria (2022) complements these insights by providing a detailed examination of the clinical manifestations and diagnostic challenges associated with CRC. Through an analysis of CRC subtypes, diagnostic modalities, and prognostic indicators, Sarandria underscores the importance of accurate disease characterization and early intervention. Their research underscores the critical role of screening programs in identifying asymptomatic individuals and highlights the need for continued efforts to improve diagnostic accuracy and treatment efficacy.

Yang et al. (2019) offer a unique perspective on CRC pathophysiology by investigating the role of chronic inflammation and epigenetic modifications in disease initiation and progression. By elucidating the molecular mechanisms underlying inflammation-induced carcinogenesis, their research provides valuable insights into potential therapeutic targets and biomarkers for CRC. Moreover, their findings underscore the dynamic interplay between environmental exposures, epigenetic alterations, and tumorigenic processes, emphasizing the need for a comprehensive understanding of CRC pathophysiology to inform precision medicine approaches.

Finally, Jahanafrooz et al. (2020) contribute to the literature by exploring the involvement of colon cancer stem cells (CCSCs) in tumor initiation and progression. Through a detailed analysis of CCSC characteristics and functions, their research highlights the challenges posed by tumor heterogeneity and treatment resistance in CRC. By elucidating the molecular mechanisms governing CCSC behavior, Jahanafrooz et al. offer valuable insights into potential therapeutic strategies targeting CRC stemness and metastasis. Their findings underscore the importance of understanding the cellular and molecular dynamics of CRC tumorigenesis to develop more effective treatment modalities.

Pathophysiology involves dysregulated signaling pathways, genetic predisposition, environmental factors, chronic inflammation, epigenetic modifications, and the presence of cancer stem cells. Integrating these findings into clinical practice can guide the development of personalized diagnostic and treatment approaches, ultimately improving patient outcomes in CRC.

Pathogenesis of Colorectal Cancer

Colorectal cancer (CRC) pathogenesis involves a multifaceted interplay of genomic and epigenomic instability, contributing significantly to disease onset and progression. One major aspect of this instability is chromosomal instability (CIN), observed in approximately 85% of CRC cases. CIN manifests as aneuploid or polyploid DNA, detectable through techniques like flow cytometry and whole exome sequencing. However, standardizing criteria for diagnosing CIN-associated CRC remains a challenge, hindering comparative analysis across studies. Microsatellite instability (MSI), accounting for around 15% of CRC cases, represents another key mechanism (Mckenzie, 2022).

Characterized by distinct mutations from CIN CRCs, MSI CRCs exhibit instability in at least 30% of microsatellite loci, often due to DNA mismatch repair gene inactivation. Furthermore, hypermethylation of CpG islands and global DNA hypomethylation play significant roles in CRC pathogenesis. Some CRCs exhibit a CpG island methylator phenotype (CIMP), marked by heightened methylation at CpG loci. The exact mechanisms driving CIMP heterogeneity remain unclear, although overexpression of DNA methyltransferases such as DNMT3B or DNMT1 correlates with CIMP. Global DNA hypomethylation is also prevalent in CRC, yet its precise implications are uncertain (Mckenzie, 2022).

Studies suggest it may induce oncogene expression or contribute to CIN development. However, conclusive insights require further investigation into its impact on CRC progression. Overall, CRC pathogenesis is intricate and heterogeneous, reflecting diverse risk factors. Continued research into its underlying cause’s promises to enhance understanding of disease mechanisms, paving the way for more effective screening, treatment, and prevention strategies in the future (Mckenzie, 2022).

(Ariyannur & Pavithran Keechilat, 2022) Investigates the molecular pathogenesis of colon adenocarcinoma (COAD) in the population of Kerala, India, where the incidence of this cancer type is on the rise. Utilizing high-throughput somatic expression analysis with the Nanostring PanCancer pathway panel assay, the study aims to identify central molecular changes and potential biomarkers specific to this demographic. Key discoveries from the research encompass the observation of significant expression differences in 83 genes out of more than 700 analyzed, with 19 genes demonstrating a fold-change of at least two, indicating notable alterations in their expression levels. Furthermore, network analysis unveils clustering of upregulated genes, hinting at potential interactions among them.

Comparative analysis with the Colon Adenocarcinoma cohort of the Cancer Genome Atlas (TCGA-COAD) dataset identifies common genes like MET, MCM2, ETV4, and MMP7. Additionally, unique genes distinctive to the Kerala population, such as INHBA, COL1A1, COL11A1, COMP, SFRP4, SPP1, IL11, LIF, WT1, and DDIT4, display significant expression differences compared to previous large cohort studies. Some of these unique genes exhibit noteworthy correlations with immune cell infiltration in the TCGA-COAD dataset. In essence, the study sheds light on potential disparities in the pathogenesis of COAD in the Kerala population in contrast to other demographics. These findings underscore the necessity for further investigation to unravel the distinct molecular mechanisms underlying COAD in this specific group, thereby offering invaluable insights for tailored interventions and personalized treatment strategies.

Clinical Correlation

Comprehending the molecular pathways implicated in colon cancer pathophysiology is essential, as it allows for correlation with clinical manifestations and symptoms, informing clinical assessment, diagnosis, and treatment decisions. Molecular pathways like chromosomal instability (CIN) and microsatellite instability (MSI) play significant roles in CRC development and progression (Mckenzie, 2022).

Clinical Assessment: understanding the molecular pathways involved in colorectal cancer (CRC) pathophysiology helps clinicians correlate specific symptoms and clinical manifestations with underlying molecular aberrations. For example, knowing that chromosomal instability (CIN) and microsatellite instability (MSI) play significant roles in CRC development, clinicians can recognize clinical signs such as changes in bowel habits, rectal bleeding, abdominal discomfort, weight loss, and fatigue as potential indicators of CRC. This correlation enhances the accuracy of clinical assessment, allowing for early detection and intervention (Mckenzie, 2022).

Diagnosis: molecular testing, including MSI testing and genetic mutation analysis, provides valuable diagnostic insights in CRC. By identifying specific molecular alterations associated with CRC subtypes, clinicians can confirm the diagnosis, differentiate between different stages or types of CRC, and predict prognosis. Clinical symptoms such as rectal bleeding or changes in bowel habits, when combined with molecular findings, help guide the diagnostic process and inform treatment decisions (Mckenzie, 2022).

Treatment Decisions: understanding the molecular basis of CRC guides personalized treatment approaches. Molecular biomarkers derived from molecular profiling stratify patients into risk groups and inform treatment selection based on individual tumor biology. For instance, certain mutations may indicate responsiveness to targeted therapies or immunotherapies. By integrating molecular insights with clinical manifestations, clinicians can tailor treatment strategies to maximize efficacy and minimize side effects (Mckenzie, 2022).

Prognosis: molecular insights provide prognostic information that helps predict disease progression and patient outcomes. For example, specific molecular alterations may correlate with more aggressive disease behavior and poorer prognosis. Clinical manifestations such as weight loss or fatigue, when considered alongside molecular findings, help clinicians assess disease severity and anticipate patient outcomes, informing treatment planning and follow-up care. (Mckenzie, 2022).

Conclusion

In summary, understanding the molecular pathophysiology of CRC enhances clinical assessment, diagnosis, and treatment decisions by correlating clinical manifestations and symptoms with underlying molecular aberrations. This integrated approach enables clinicians to provide more accurate diagnoses, tailor treatment strategies to individual patients, and predict disease progression, ultimately improving patient outcomes.

This investigation has provided an analysis of the molecular pathways involved in colorectal cancer (CRC) pathophysiology and their correlation with clinical manifestations and symptoms. We discussed how understanding these molecular mechanisms informs clinical assessment, diagnosis, and treatment decisions in CRC patients. Key points highlighted include the contribution of chromosomal instability (CIN) and microsatellite instability (MSI) to CRC development, the significance of molecular testing in clinical assessment, the role of molecular profiling in enhancing diagnosis and treatment selection, and the importance of personalized medicine based on tumor biology. As an advanced practice nurse, comprehending the molecular pathophysiology of CRC is crucial for providing holistic care to patients. By integrating molecular insights into clinical practice, advanced practice nurses can optimize patient outcomes through personalized and evidence-based care strategies.

Referencias Ariyannur, P., & Pavithran Keechilat. (2022). ascopubs. Recuperado el 15 de 03 de 2024, de Evaluation of molecular pathogenesis of colon cancer in Kerala using high-throughput expression, signaling pathways, and network analyses.: https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.e16065 mayoclinic. (2022). Recuperado el 15 de 03 de 2024, de Colon cancer: https://www.mayoclinic.org/diseases-conditions/colon-cancer/symptoms-causes/syc-20353669 Mckenzie, S. (2022). news-medical. Recuperado el 15 de 03 de 2024, de Colorectal Cancer Pathogenesis: https://www.news-medical.net/health/Colorectal-Cancer-Pathogenesis.aspx#:~:text=Colorectal%20cancer%20development%20begins%20with,circumference%20of%20the%20colon%2Frectum. Baishideng. (2019). Role of epigenetics in transformation of inflammation into colorectal cancer: https://www.wjgnet.com/1007-9327/abstract/v25/i23/2863.htm Chakrabarti, S., Peterson, C. Y., Sriram, D., & Mahipal, A. (2020). Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions. World Journal of Gastrointestinal Oncology, 12(8), 808–832. https://doi.org/10.4251/wjgo.v12.i8.808 Jahanafrooz, Z., Mosafer, J., Akbari, M., Hashemzaei, M., Mokhtarzadeh, A., & Baradaran, B. (2020). Colon cancer therapy by focusing on colon cancer stem cells and their tumor microenvironment. Journal of Cellular Physiology, 235(5), 4153-4166. https://doi.org/10.1002/jcp.29337 Malki, A., ElRuz, R. A., Gupta, I., Allouch, A., Vranic, S., & Al Moustafa, A. E. (2020). Molecular mechanisms of colon cancer progression and metastasis: Recent insights and advancements. International Journal of Molecular Sciences, 22(1), 130. https://doi.org/10.3390/ijms22010130 Ri-Na Yoo, H.-M. C.-H. (2021). NIH. Management of obstructive colon cancer: Current status, obstacles, and future directions: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713324/ Sarandria, N. (2022). A literature review in immuno-oncology: Pathophysiological and clinical features of colorectal cancer and the role of the doctor-patient interaction. Journal of Cancer Therapy, 13(12), 654-684. https://doi.org/10.4236/jct.2022.1312059 Yang, Z. H., Dang, Y. Q., & Ji, G. (2019). Role of epigenetics in transformation of inflammation into colorectal cancer. World Journal of Gastroenterology, 25(23), 2863–2877. https://doi.org/10.3748/wjg.v25.i23.2863

Assignment: Advanced Pathophysiology Analysis

In this assignment, you will conduct A comprehensive analysis of the molecular mechanisms underlying a specific disease or condition of your choice. The purpose of this assignment is to enhance your understanding of advanced pathophysiology concepts and their application to clinical practice, as well as to explore the latest research findings and therapeutic implications related to selected diseases.

The objectives of this assignment include being able to critically analyze the molecular mechanisms underlying the development and progression of a chosen disease or condition, evaluate the role of genetic, environmental, and immunological factors in pathophysiology, and to demonstrate a comprehensive understanding of advanced pathophysiology concepts through the application of molecular mechanisms to clinical manifestations of the selected disease.

This assignment will focus on the following course student learning outcomes (CSLO):

1. Evaluate the concepts of cellular biology and altered cellular and tissue biology for their implications to disease management (EOPSLO# 1). 

2. Distinguish knowledge of normal physiology and pathologic alterations across the lifespan that are expressed as diseases of organs and systems (EOPSLO# 1, 9). 

3. Analyze current research findings with evidence-based guidelines for the management of selected diseases (EOPSLO# 4, 9). 

Instructions: Please choose one disease or condition being learned in the course. Once the disease or condition is chosen, you are to write a three-to-five-page paper in APA format 7th edition with the following sections and level 2 headings:

Introduction

-Brief overview of the definition of pathophysiology

-Introduce the disease condition chosen

-Importance of understanding pathophysiology

Literature Review

-conduct A thorough literature review to explore the molecular pathophysiology of the chosen disease.

-Identify and analyze peer reviewed articles, research studies, and/or scholarly sources to define molecular mechanisms, genetic factors, environmental triggers, and/or immunological pathways associated with the condition.

Pathogenesis

-provide a detailed analysis of the molecular mechanisms underlying the pathogenesis and progression of the chosen disease. This may include genetic predisposition, dysregulation of immune responses, cellular signaling pathways, and tissue-specific effects.

Clinical Correlation

-correlate the identified molecular pathways with the clinical manifestations and symptoms of the chosen disease.

-Discuss how an understanding of the molecular pathophysiology can inform clinical assessment, diagnosis, and treatment decisions.

Conclusion

-Recap points discussed in paper

-Importance of understanding pathophysiology as an advanced practice nurse.

References

-Please include at least 5 references on its own page, within the last 5 years with included in-text citations.

Sickle cell anemia statistics in United States 2024

https://www.cdc.gov/sickle-cell/data/index.html

· Sickle cell disease (SCD) affects about 100,000 people in the United States.

· The estimated life expectancy of those with SCD in the United States is more than 20 years shorter than the average expected.

· More than 90% of people in the United States with SCD are non-Hispanic Black or African American (Black), and an estimated 3%–9% are Hispanic or Latino.

· SCD occurs in about 1 out of every 365 Black or African American births and about 1 out of every 16,300 Hispanic American births.

· About 1 in 13 Black or African American babies is born with sickle cell trait (SCT, inheritance of a sickle cell gene from only one parent).

https://www.medicalnewstoday.com/articles/how-common-is-sickle-cell-anemia#prevalence

· SCD affects approximately 100,000 people in the United States.

· around 1 out of every 365 Black or African American babies have SCD

· around 1 out of every 16,300 Hispanic American babies have SCD

According to the CDC, approximately 1 in 13Trusted Source Black or African American babies have SCT.

https://www.nhlbi.nih.gov/health/sickle-cell-disease

Sickle cell disease affects more than 100,000 people in the United States and 8 million people worldwide. In the United States, 9 of 10 people who have sickle cell disease are of African ancestry or identify as Black:

· About 1 in 13 Black babies are born with  sickle cell trait, meaning that they inherited a sickle cell gene from one parent. 

· About 1 in every 365 Black babies are born with sickle cell disease, meaning they inherited a sickle cell gene from each parent.

https://medlineplus.gov/sicklecelldisease.html

· About 1 in 13 Black or African American babies are born with sickle cell trait

· About 1 in every 365 Black or African American babies are born with sickle cell disease

https://www.hematologyadvisor.com/features/sickle-cell-disease-fact-sheet-important-things-to-know/

In the United States, about 1 in every 365 Black or African American infants and 1 in every 16,300 Hispanic American infants in the United States are born with SCD.